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Abstract 
Virus infections possess persistent health challenges in swine industry leading to severe economic losses worldwide. 
The economic burden caused by virus infections such as Porcine Reproductive and Respiratory Syndrome Virus, Swine 
influenza virus, Porcine Epidemic Diarrhea Virus, Porcine Circovirus 2, Foot and Mouth Disease Virus and many others 
are associated with severe morbidity, mortality, loss of production, trade restrictions and investments in control and 
prevention practices. Pigs can also have a role in zoonotic transmission of some viral infections to humans. Inacti-
vated and modified-live virus vaccines are available against porcine viral infections with variable efficacy under field 
conditions. Thus, improvements over existing vaccines are necessary to: (1) Increase the breadth of protection against 
evolving viral strains and subtypes; (2) Control of emerging and re-emerging viruses; (3) Eradicate viruses localized 
in different geographic areas; and (4) Differentiate infected from vaccinated animals to improve disease control 
programs. Nanoparticles (NPs) generated from virus-like particles, biodegradable and biocompatible polymers and 
liposomes offer many advantages as vaccine delivery platform due to their unique physicochemical properties. NPs 
help in efficient antigen internalization and processing by antigen presenting cells and activate them to elicit innate 
and adaptive immunity. Some of the NPs-based vaccines could be delivered through both parenteral and mucosal 
routes to trigger efficient mucosal and systemic immune responses and could be used to target specific immune 
cells such as mucosal microfold (M) cells and dendritic cells (DCs). In conclusion, NPs-based vaccines can serve as 
novel candidate vaccines against several porcine viral infections with the potential to enhance the broader protective 
efficacy under field conditions. This review highlights the recent developments in NPs-based vaccines against porcine 
viral pathogens and how the NPs-based vaccine delivery system induces innate and adaptive immune responses 
resulting in varied level of protective efficacy.
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1  Economically important viral infections of pigs
Viruses are the obligate intracellular nano‑sized particles, 
which depend on host cell machinery for propagation 
and survival. They carry deoxyribonucleic acid (DNA) 
or ribonucleic acid (RNA) as their genomic material. 
There are several viruses from both DNA and RNA virus 
families that infect and produce disease in pigs [1]. There 
are many economically important swine viral infections 
which cause considerable morbidity and mortality, and 
responsible for significant economic losses to the pork 
industry (Table 1). Depending on their cellular and tissue 
tropisms, viruses cause pathological changes and clini‑
cal signs associated with respiratory system, reproduc‑
tive and gastrointestinal tracts, nervous system, skin and 
extremities, alone or in combinations [1, 2].
1.1  Diseases caused by RNA viruses
Porcine reproductive and respiratory syndrome virus 
(PRRSV), an enveloped and positive‑stranded RNA virus 
of Arteriviridae family, causes porcine reproductive and 
respiratory syndrome (PRRS) [3]. PRRS is responsible for 
over one billion dollar loss per year through direct and 
indirect costs in the US swine industry [4]. Two entirely 
distinct genotypes of PRRSV circulate in European (gen‑
otype 1/PRRSV 1) and North American countries (geno‑
type 2/PRRSV 2) and cause tremendous economic loss. 
PRRSV is transmitted through oral‑nasal secretions and 
semen. The clinical signs include fever, anorexia, mild to 
severe respiratory problems, abortion and reproductive 
failures. It is the most common pathogen associated with 
porcine respiratory disease complex (PRDC) [3].
Swine influenza (flu) constitutes another persistent 
health challenge to the global pig industry. Flu infec‑
tion is caused by influenza A virus of Orthomyxoviri‑
dae family which has negative‑sense, single‑stranded, 
segmented RNA genome. Influenza virus is transmitted 
through direct contact with infected animals or contami‑
nated fomites, aerosols and large droplets [5]. The clinical 
signs of influenza infection include fever, anorexia, loss of 
weight gain and respiratory problems. Influenza associ‑
ated economic losses are due to morbidity, loss of body 
weight gain, increased time to market, secondary infec‑
tions, medication and veterinary expenses [6]. Influenza 
of swine origin occasionally infect humans and can even 
lead to pandemics as of 2009 [7].
Porcine epidemic diarrhea virus (PEDV), transmissible 
gastroenteritis virus (TGEV) and porcine deltacorona‑
virus (PDCoV) are enteric pathogens of young pigs [8]. 
These viruses belong to Coronaviridae family and have 
positive‑sense, single‑stranded RNA genome. TGEV did 
serious economic damage to the swine industry in 1990s 
but with the advent of vaccines it has been largely con‑
trolled [8]. PEDV still results in high morbidity and mor‑
tality in neonatal piglets with clinical signs like severe 
diarrhea, vomiting, dehydration and death. In 2013/14, 
PEDV outbreak in the US led to over a billion‑dollar loss 
Table 1 Economically important viral diseases of pigs 
Disease Virus Epidemiology Clinical signs References
Porcine reproductive and respira-
tory syndrome (PRRS)
PRRS virus (PRRSV)
Single strand (+) RNA
Worldwide Fever, anorexia, mild to severe 
respiratory problems, abortion, 
reproductive failures
[3]
Swine influenza Influenza A virus (IAV)
Single strand (−) RNA
Worldwide Fever, anorexia, loss of weight 
gain, respiratory problems
[5, 28]
Porcine epidemic diarrhea (PED) PED virus (PEDV)
Single strand (+) RNA
Worldwide Severe diarrhea, vomiting and 
dehydration
[115]
Foot and mouth disease (FMD) FMD virus (FMDV)
Single strand (+) RNA
Parts of Asia, Africa, Middle East 
and South America
Fever, inappetence, vesicular 
lesions on extremities
[11]
Classical swine fever (CSF)/hog 
cholera
CSF virus (CSFV)
Single strand (+) RNA
Endemic in Central America, Africa, 
Asia and parts of South America
Fever, anorexia, erythema, respira-
tory signs, neurological signs, 
reproductive failures, death
[13]
Porcine circovirus associated 
disease (PCVAD)
Porcine circovirus 2 (PCV2)
Single strand DNA
Worldwide Poor weight gain, respiratory 
problems, dermatitis, enteritis, 
nephropathy, reproductive 
failures
[16]
Porcine parvovirus infection Ungulate parvovirus 1
Single strand DNA
Worldwide Stillbirth, mummification, embry-
onic death, infertility
[17]
Pseudorabies/Aujeszky’s disease Suid herpesvirus 1
Double strand DNA
China and parts of Europe, Asia 
and Latin America
Nervous disorders, respiratory 
problems, weight loss
[18, 19]
African swine fever (ASF) ASF virus (ASFV)
Double strand DNA
Endemic in sub-Saharan Africa, 
Sardinia, Caucasus region and 
Eastern Europe
Fever, anorexia, erythema, respira-
tory signs, reproductive failures, 
death
[13]
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[9]. Rotaviruses are double‑stranded RNA viruses of Reo-
viridae family, cause enteric infections in pigs. Rotavirus 
of groups A, B, C, E and H are involved in porcine enteric 
infections. Some of these porcine rotaviruses also have 
zoonotic potential [10].
Foot and mouth disease (FMD) is another highly con‑
tagious, acute viral disease in pigs. The etiologic agent, 
FMD virus (FMDV), is a positive‑sense, single‑stranded 
RNA virus of Picornaviridae family [11]. FMDV is trans‑
mitted through direct contact with infected animals or 
contaminated sources. Clinical signs include high fever, 
appearance of vesicular lesions on the extremities, sali‑
vation, lameness and death. FMDV causes frequent epi‑
zootics in many parts of the world resulting in severe 
economic loss, food insecurity and trade restrictions [11].
Classical swine fever (CSF) or hog cholera can result 
in high morbidity and mortality in pigs. It is caused by 
CSF virus (CSFV), an enveloped, positive‑sense, single‑
stranded virus of Flaviviridae family. Transmission of 
CSFV occurs through oral‑nasal routes after contact with 
infected pigs or contaminated resources and even verti‑
cally from infected sows to piglets [12]. Clinical signs 
include fever, anorexia, respiratory problems, neuro‑
logical disorders, reproductive failures and death. CSF 
is a notifiable disease to World Organization for Ani‑
mal Health (OIE). The economic losses are associated 
with production loss, trade limitations and tremendous 
expenditures in eradication programs [13]. For example, 
the 1997/98 outbreak of CSFV in the Netherland resulted 
in death of 9 million pigs and economic losses of 2.3 bil‑
lion dollars [14]. United States is free of CSFV; however, 
this virus is endemic in many parts of the world including 
Central and South America, Africa and Asia.
1.2  Diseases caused by DNA viruses
Porcine circovirus 2 (PCV2), a single‑stranded DNA 
virus of Circoviridae family, causes multi‑systemic dis‑
ease referred as porcine circovirus‑associated disease 
(PCVAD). PCV2 is transmitted horizontally as well as 
vertically. Direct contact is the most efficient way of 
horizontal transmission of this virus. The clinical signs 
of PCV2 infection include poor weight gain, respiratory 
problems, dermatitis, enteritis, nephropathy and repro‑
ductive failures [15]. Five genotypes of PCV2 (PCV2a to 
PCV2e) are identified and circulate with high prevalence 
in swine herds causing significant economic losses world‑
wide [16].
Porcine parvovirus (PPV) is the common cause of 
reproductive failure in swine herds. This single‑stranded 
DNA virus of Parvoviridae family is transmitted through 
oral‑nasal routes. Stillbirths, mummification, embry‑
onic death, and infertility (SMEDI syndrome) are linked 
to PPV infection. Conventionally, PPV was considered 
genetically conserved but recent evidences suggest that 
several virulent strains have emerged due to its high 
mutation rate [17].
Aujeszky’s disease or pseudorabies in pigs is caused by 
Suid herpesvirus 1, a double stranded DNA virus belong‑
ing to Herpesviridae family. The causative agent is spread 
primarily through direct animal‑to‑animal (nose‑to‑nose 
or sexual) contact. Pseudorabies is characterized by nerv‑
ous disorders, respiratory problems, weight loss, deaths 
in younger piglets and reproductive failures; and is one of 
the most devastating infectious diseases in pig industry 
[18, 19].
African Swine Fever (ASF) causes hemorrhagic infec‑
tion with high morbidity and mortality. The etiologic 
agent, ASF virus (ASFV), is a double stranded DNA virus 
of Asfarviridae family [20]. Virus transmission occurs 
through direct contact with infected animals, indirect 
contacts with fomites or through soft tick species of the 
genus Ornithodoros. Clinical disease may range from 
asymptomatic infection to death with no signs. Acute 
infections are characterized by high fever, anorexia, 
erythema, respiratory distress, reproductive failure in 
pregnant females and death [20]. ASF is OIE notifiable 
disease. United States is free of ASFV, however, this virus 
is endemic in domestic and wild pig population in many 
parts of the world with possibility of transmission to the 
US and other nonendemic regions through animal trades 
[13]. The economic losses are associated with production 
loss, trade limitations and tremendous expenditures in 
eradication programs [13].
Besides the RNA and DNA viruses described above, 
many other emerging and re‑emerging viruses such as 
porcine hepatitis E virus, porcine endogenous retrovirus, 
porcine sapovirus, Japanese encephalitis virus, encepha‑
lomyocarditis virus and others cause variable degree of 
impact in swine health and economic losses in pig indus‑
try globally [2, 21, 22].
2  Vaccination against porcine viral infections
Different types of vaccines that are available against eco‑
nomically important swine viruses are listed in Table  2. 
Vaccines against PRRSV are being used in the US since 
1980s [23]. Both inactivated and modified‑live virus vac‑
cines are available and used globally. These vaccines are 
effective in reducing clinical disease and viremia mainly 
against homologous but not against heterologous infec‑
tions [24]. Therefore, different strategies are ongoing to 
develop live, inactivated, subunit and mucosal PRRSV 
vaccines to induce better immunity and broader protec‑
tion [23, 25–27]. Swine influenza vaccines are also most 
effective when the vaccine strains closely match with the 
circulating strains [5, 28].
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To increase the immunity and protection, vaccines 
containing multiple strains of influenza A virus (IAV) 
and autogenous vaccines are widely used [5, 28]. Co‑
circulation of multiple lineages of IAV and frequent 
antigenic drift are responsible for reduced field efficacy 
of current swine influenza vaccines. Moreover, the most 
commonly used whole inactivated IAV vaccines admin‑
istered via intramuscular route do not induce adequate 
mucosal antibody and cellular immune responses, suffer 
maternal antibody interference in young piglets and even 
can cause enhanced respiratory disease [5, 28].
The emergence of highly virulent strains of PEDV in 
recent years has highlighted the need of safe and effec‑
tive vaccines against porcine enteric coronaviruses that 
prevents clinical disease, mortality and virus shedding in 
neonates [8]. Modified live vaccines against rotavirus are 
available for use in pigs against rotavirus A but their effi‑
cacy under field conditions is questionable indicating the 
need of alternatives for porcine rotavirus management 
[10].
The available inactivated vaccines provided great help 
in prevention and control of FMD outbreaks in many 
countries. However, the development of these vaccines 
needs high level biocontainment facilities. Further, the 
FMDV serotypes undergo continuous antigenic drift 
and escape the vaccine‑induced immunity [29]. Thus, 
FMD vaccines with less stringent regulatory procedures 
and multi‑serotype protective efficacy are needed in the 
future. Safe and highly efficacious live‑attenuated vac‑
cines are available against CSFV but differentiation of 
infected from vaccinated animals (DIVA) is not possible 
with these vaccines, which limit their use during out‑
break control or disease eradication programs [30].
Inactivated whole virus or subunit vaccines based 
on PCV2a are highly adopted in pig farms and are 
efficacious in reducing clinical signs and improving 
the production parameters. However, infections are 
still widespread in vaccinated farms [16, 31]. Further, 
the replacement of PCV2a to PCV2b and recently to 
PCV2d is in part contributed by the selection pressure 
exhibited by PCV2a‑based vaccines [32] which high‑
lights the need of vaccines that protect against multiple 
genotypes.
The currently used inactivated vaccines of porcine 
parvo virus protect against old PPV strains but not 
against the newly emerging strains demanding for more 
efficacious vaccines [17, 33]. Fortunately, pseudorabies 
has been eradicated in many countries including the US 
by using inactivated and attenuated vaccines together 
with stringent biosecurity measures. However, it is 
still a problematic disease in many countries including 
China and is also maintained in feral swine populations 
in other countries [18, 34]. The frequent emergence of 
virulent strains even in the vaccinated herds demands 
updated vaccine technology to achieve efficient control 
and ultimate global eradication of pseudorabies [19, 
34].
Vaccine is not available so far against ASFV, and 
the control measures depend entirely on early identi‑
fication and culling of infected herds and adoption of 
strict sanitary measures [35]. Vaccine development is 
hindered by the antigenic diversity and multitude of 
immune‑evasion strategies used by the virus. An effec‑
tive vaccine will definitely help in control and eradica‑
tion of ASFV from endemic countries and prevent its 
geographical expansion [20].
Table 2 Vaccines available against economically important porcine viral infections 
Disease Vaccines available Improvements needed References
Porcine reproductive and respiratory syndrome 
(PRRS)
Inactivated, modified-live virus Rapid immune induction
Heterologous protection
No adverse impact on health
[23, 24]
Swine influenza Inactivated, modified-live virus Broader protection
No maternal antibody interference
No vaccine-enhanced disease
[5, 28]
Porcine epidemic diarrhea (PED) RNA particle, inactivated and 
live-attenuated virus (in Asia)
Protective immune response in sows
Better mucosal immunity
[8, 9]
Foot and mouth disease (FMD) Inactivated virus Less stringent requirements in vaccine produc-
tion
Protection against multiple serotypes
[29]
Classical swine fever (CSF) Live-attenuated virus DIVA potential [30]
Porcine circovirus associated disease (PCVAD) Inactivated, recombinant subunit Multi-genotype protection [16, 31]
Porcine parvovirus infection Inactivated virus Protection against novel strains [17, 33]
Pseudorabies Inactivated, live-attenuated virus Protection against novel emerging strains [18, 19]
African swine fever (ASF) None Novel cross-protective vaccine [20]
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3  Importance of nanoparticle‑based vaccine 
delivery platforms
Development of vaccines has made significant impact 
on reducing the viral infectious disease burden in both 
humans and animals. However, there are still many dis‑
eases for which either we do not have vaccines or need 
substantial improvements over existing ones [36, 37]. In 
the past few decades, nanoparticles (NPs)‑based tech‑
nologies have elicited significant interests in the develop‑
ment of novel vaccine candidates as they offer multiple 
benefits over inactivated virus or subunit soluble anti‑
gens. NPs‑based vaccines (nanovaccines) are prepared 
either by encapsulating vaccine components within the 
NPs or by decorating the particle surface with viral anti‑
gens. NPs protect antigens from proteolytic degrada‑
tion, prolong their bioavailability and maintain slow and 
sustained antigen release. All of these properties help 
in induction of better immune responses compared to 
soluble antigen vaccines [38]. The different mechanisms 
used by various NPs to facilitate immune modulation of 
antigen presenting cells (APCs) are depicted graphically 
in Figure 1. Briefly, NPs can enhance antigen adsorption 
and uptake by APCs; they can also facilitate antigen pro‑
cessing mechanisms; NPs can induce maturation of DCs 
and promote antigen cross‑presentation through major 
histocompatibility complex (MHC) class I to  CD8+ T 
cells; and induce production of different innate cytokines 
that regulate humoral and cellular immune responses. 
NPs‑loaded antigens are readily phagocytosed by APCs; 
soluble antigens are not [39]. Moreover, dendritic cells 
(DCs), the key player involved in bridging innate and 
adaptive immunity, preferentially internalize NPs com‑
pared to microparticles (> 1000 nm). For example, when 
poly(lactic‑co‑glycolic acid) (PLGA) particles of size 
300  nm to 17  µm encapsulating ovalbumin were tested 
on mouse bone‑marrow derived dendritic cells, 300 nm 
sized particles were taken up efficiently compared to 
larger ones [40]. The 300 nm sized PLGA NPs resulted in 
greater activation of DCs and stronger antigen‑specific T 
cells responses in immunized mice compared to soluble 
antigens and larger particles [40].
Besides controlled delivery of antigens, NPs also pro‑
vide adjuvant‑like functions. Vaccine adjuvants either 
work as antigen delivery systems facilitating antigen 
uptake and presentation by APCs or they activate innate 
immune receptors for cytokine production and matura‑
tion/migration of DCs [41]. Adjuvant‑induced innate 
immune responses determine the type of adaptive 
immune responses generated such as T helper 1 (Th1) 
versus T helper 2 (Th2)‑biased immunity [42]. Alum, 
the most widely used adjuvant in humans, is safe and 
inexpensive. Its compatibility has been proved favorable 
with different vaccine antigens. However, despite induc‑
ing potent antibody responses, alum is a weak‑inducer of 
cell‑mediated immunity. Adverse reactions are observed 
at injection site with alum‑based adjuvants [43, 44]. In 
veterinary vaccines, oil‑in‑water emulsions or saponins 
are the most common adjuvants. These can also cause 
adverse reactions at the injection sites [45, 46]. While 
number of adjuvants are available for parenteral vacci‑
nations, very limited options are available for intranasal 
(IN) or other alternative routes of immunization [41, 47, 
48]. NPs can serve as an alternative adjuvant for human 
and animal use as they act both as antigen delivery sys‑
tem and activate the innate immune responses [49–51]. 
Further, the modern vaccination approach has shifted 
from traditional whole pathogen‑based antigens to small 
fraction (subunit) of the pathogen. However, purified 
whole inactivated pathogen and subunit or recombi‑
nant antigens by themselves are poorly immunogenic 
and require a potent immunostimulatory platform to 
augment the immune response. This can be achieved 
through NPs‑based technologies [47, 52].
NPs‑based platforms can be used to deliver multi‑
ple antigens or antigen/adjuvant combinations, which 
improves antigen uptake and concurrent activation of 
APCs leading to innate immune programming [53, 54]. 
Co‑delivery of CpG oligodeoxynucleotide and tetanus 
toxoid in nanospheres induced significantly greater T 
cell proliferative response and 5 to 16 times greater IgG 
antibody isotypes in mice after subcutaneous immuniza‑
tion compared with the group that received tetanus tox‑
oid and CpG oligodeoxynucleotide in soluble form [54]. 
Likewise, co‑delivery of melanoma antigen and Toll‑like 
receptor (TLR) 4 agonist in PLGA NPs induced therapeu‑
tic anti‑tumor effects that are mediated through potent 
 CD8+ T cell activation [55]. NPs can be surface modified 
Figure 1 Schematic representation of different effects imparted 
by NPs on APCs. NPs-based vaccines can—(1) enhance antigen 
uptake; (2) facilitate antigen processing; (3) induce maturation of DCs; 
(4) promote antigen cross-presentation by MHC-I; and (5) induce 
cytokine production.
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to target microfold (M) cells, macrophages or DCs, and 
could be used for mucosal vaccination through oral, nasal 
or other mucosal routes of immunization. In mice, sur‑
face coating of PLGA NPs encapsulating hepatitis B virus 
vaccine antigens with lectin resulted in efficient target‑
ing of oral delivered NPs to mucosal M cells and induced 
secretary IgA antibody response in mucosal surfaces 
[56]. Likewise, DCs targeted chitosan NPs loading plas‑
mid DNA encoding nucleocapsid protein of Severe Acute 
Respiratory Syndrome Coronavirus (SARS‑CoV) induced 
better nucleocapsid protein‑specific mucosal IgA anti‑
body response compared to soluble unentrapped anti‑
gens after nasal immunization in mice [57].
A targeted T‑cell mediated immune response is criti‑
cal in protection against intracellular pathogens such as 
viruses. Beneficially, NPs‑delivered antigens are useful 
in antigen cross‑presentation to cytotoxic T lympho‑
cytes (CTLs) and development of robust cell‑mediated 
immune response [58, 59]. PLGA‑based particulate vac‑
cines are shown to induce efficient T‑cell immunity in 
mice and pigs [60–63]. Similarly, rodent and pig stud‑
ies have shown that polyanhydride NPs‑based vaccines 
also enhance cellular immunity [50, 64]. Thus, immuno‑
genic properties of different polymer‑based NPs could 
be exploited to improve the efficacy of vaccines for use 
against porcine viral infections.
4  Particulate vaccines and porcine viral infections
In this review, only studies conducted in pigs related to 
the development and evaluation of NPs‑based vaccine 
candidates by using virus‑like particles (VLPs), bio‑
degradable polymers, polysaccharides and liposomes 
against porcine viral infections are included (Table 3).
4.1  Virus‑like particles (VLPs)
VLPs are constructed using viral structural proteins, 
which can self‑assemble but are non‑infectious as they 
lack the viral genomic material. VLPs mimic the virion 
and can effectively induce innate and adaptive immune 
responses [65]. VLPs are produced using different bac‑
terial, insect, yeast or mammalian expression systems 
[66]. Due to their smaller size and particulate nature, 
VLPs‑based vaccines are processed and presented not 
only through MHC class II but also through MHC class 
I pathway leading to the generation of antibodies as well 
as CTL responses [67, 68]. The potential use of VLPs in 
porcine viral vaccine development is evident through the 
success in commercialization of Human Papilloma Virus 
(HPV), Hepatitis B virus and malaria vaccines by adapt‑
ing this technology [69].
In one study, PRRSV VLPs containing five (GP5, GP4, 
GP3, GP2a and M) and two (GP5 and M) viral surface 
proteins were generated using the baculovirus expression 
system. PRRSV VLPs vaccine was mixed at 1:1 ratio with 
Mycobacterium tuberculosis whole cell lysate (M. tuber-
culosis WCL) adjuvant and administered INto pigs. 
VLPs‑vaccinated pigs were partially protected with 2‑log 
reduction of virus titers in lungs. VLPs‑vaccinated pigs 
also had enhanced IFN‑γ response compared to mock 
challenge pigs [70]. However, in another study, when pigs 
were vaccinated IN with PRRSV VLPs expressing N, M, 
GP5 and E proteins, enhanced viremia accompanied with 
higher level of IFN‑α cytokine response was observed 
[71]. The contrasting results in PRRSV VLPs study sug‑
gest the need for further research to fully evaluate the 
potential of VLPs‑based PRRSV vaccines for swine.
Influenza‑associated VLPs expressing HA, NA and M1 
proteins of pandemic 2009 (H1N1) virus were inoculated 
twice intramuscularly with or without Emulsigen (MVP 
Lab, USA) adjuvant to pigs. This vaccine induced robust 
serum IgG, mucosal IgA and virus neutralizing antibody 
responses in pigs. After homologous virus challenge, 
VLPs‑vaccinated pigs had significantly reduced pneu‑
monic lesions and virus titers were substantially lowered 
in upper and lower respiratory tracts compared to mock 
vaccinated animals [72].
Many studies have been conducted with the goal to 
develop VLPs‑based FMDV vaccine using various expres‑
sion systems encoding different viral antigens. Rabbit 
hemorrhagic disease virus (RHDV) VLPs expressing 
T‑cell epitope of 3A protein of FMDV (RHDV‑3A‑VLPs) 
was generated. This VLPs vaccine induced maturation of 
bone marrow derived dendritic cells in  vitro [73]. Pigs 
immunized IM with RHDV‑3A‑VLPs together with Mon-
tanide ISA 206 adjuvant (Seppic, France) induced higher 
serum IgG and IgA antibody responses. This vaccine 
also increased number of IFN‑γ secreting cells and lym‑
phoproliferative responses in PBMCs compared to vac‑
cine delivered without adjuvant and IN RHDV‑3A‑VLPs 
inoculated pigs; however, challenge experiments were 
not performed [73]. Guo et al. constructed FMDV VLPs 
expressing capsid proteins VP0, VP1 and VP3 and immu‑
nized pigs by IM route [74]. VLPs‑vaccinated pigs pro‑
duced virus‑specific neutralizing antibodies and IFN‑γ 
response in peripheral blood mononuclear cells (PBMCs) 
as good as the inactivated FMDV vaccine control. After 
challenge with homologous virus, VLPs‑vaccinated 
pigs did not show specific clinical signs [74]. In another 
study, VP1 epitope peptides (EP141‑160) of FMDV were 
inserted into the coat protein genes of male‑specific 
coliphage (MS2) (CP‑EP141‑160 VLPs) and injected IM 
to pigs. This formulation resulted in induction of virus 
neutralizing antibodies and protected 60% of the immu‑
nized pigs compared to only 20% protection in peptide 
alone vaccinated animals. However, the protection was 
lower than inactivated vaccine (80%) indicating the need 
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of further improvement in this VLPs either by using 
longer sequence of epitope or addition of other adju‑
vants [75]. VLPs generated by insertion of VP1 epitopes 
of FMDV into porcine parvovirus VP2 were administered 
IM to pigs. This VLPs‑vaccine induced higher virus neu‑
tralizing antibodies compared to synthetic peptide vac‑
cine and resulted in better protection to challenge FMDV 
infection [76].
VLPs have also been developed and tested against 
porcine neurotropic viruses [21, 22]. Porcine encepha‑
lomyocarditis virus (EMCV) VLPs containing structural 
protein P1, nonstructural protein 2A and protease 3C 
were generated. After IM administration together with 
Montanide IMS 1313 N VG adjuvant (Seppic), VLPs‑vac‑
cine induced sustained production of virus neutralizing 
antibodies comparable to commercial vaccine control. 
There was absence of any severe injection site reactions 
in VLPs‑vaccinated pigs [21]. This suggests the potential 
of developing VLPs‑based vaccine against EMCV disease 
in pigs. Likewise, in a recent study, Japanese encephali‑
tis virus genotype I (GI) VLPs encoding premembrane 
(prM) and envelope (E) proteins were constructed. After 
subcutaneous immunization, this vaccine formulation 
induced robust neutralizing antibody response and pro‑
tection against both homologous GI and heterologous 
GIII JEVs viruses. This finding indicates the cross‑protec‑
tion potential of VLPs‑based JEV vaccine in pigs [22].
Early study on PCV2 VLPs used full length Cap pro‑
tein in Escherichia coli expression system [77]. Pigs vac‑
cinated against PCV2 using Cap VLPs and ISA 201 
adjuvant (Seppic) by IM route induced Cap‑specific IgG 
antibodies. Vaccinated animals were apparently healthy 
with normal body weight gain and absence of any clini‑
cal signs of disease [77]. Li et al. [78] showed induction 
of Cap‑specific IgG antibodies in pigs vaccinated by sub‑
cutaneous (SC) injection of Cap VLPs. Vaccinated pigs 
demonstrated reduced fever, viremia and mild patho‑
logical changes in lungs and lymph nodes compared to 
unvaccinated challenge animals. In another study, VLPs 
co‑expressed with Cap protein and porcine GM‑CSF 
were administered IM to pigs. This vaccine formulation 
induced significantly higher virus neutralizing antibodies 
in pigs. After virus challenge, VLPs‑vaccinated pigs had 
normal body weight gain compared to Cap protein alone 
and commercial PCV2 vaccine groups. Virus clearance, 
however, was observed in equally in VLPs as well as other 
control vaccine groups [79].
Only a single VLPs‑based vaccine study for porcine 
parvovirus was found [80]. PPV‑VLPs expressing major 
structural protein VP2 were administered IM with double 
oil emulsion (DOE) mineral oil adjuvant to weaned pigs. 
There was an induction of significantly higher neutral‑
izing antibodies in VLPs‑vaccinated animals compared 
to inactivated vaccine group. Further, when gilts immu‑
nized with this formulation were challenged with virulent 
PPV, virus was not detected in any of the fetuses. Thus, 
PPV‑VLPs can be a potential vaccine candidate to pre‑
vent PPV‑induced reproductive failure [80]. In summary, 
VLPs of various origin can be used to develop more effi‑
cient vaccines against porcine viral infections. Further 
studies are needed to evaluate their immunogenicity and 
protective efficacy under field conditions.
4.2  Biodegradable synthetic PLGA NPs
PLGA is a co‑polymer of lactic acid and glycolic acid. It 
is the most widely explored synthetic polymer in vac‑
cine studies. It is a safe and non‑toxic compound, and 
its hydrolysis products are readily assimilated into exist‑
ing metabolic pathways [81]. PLGA nanoparticles are 
prepared either by oil in water emulsification or nano‑
precipitation methods [82, 83]. PLGA NPs bear a net 
negative charge. They enter APCs through pinocytosis 
and endocytosis, undergo reversal of charge and endo‑
lysosomal escape of entrapped vaccine cargo leading to 
antigen processing in cytoplasm, resulting in cross‑pres‑
entation of antigen to  CD8+ T cells through MHC class I 
pathway [59, 82]. PLGA NPs are involved in maturation 
of DCs of mice and human origin, and controlled release 
of entrapped antigens leading to efficient expansion and 
differentiation of memory T‑cells [84, 85]. In rodent stud‑
ies, induction of robust T‑cell immunity is observed with 
PLGA NPs‑based vaccines containing various vaccine 
antigens [55, 82]. Further, PLGA is approved for drug 
deliveries in humans by the US Food and Drug Admin‑
istration (FDA) and European Medicine Agency (EMA) 
[82].
PLGA NPs enhance antigen uptake and induce matu‑
ration of porcine APCs [62, 86, 87]. Single dose of IN 
immunization with PLGA NPs‑encapsulated inactivated/
killed PRRSV antigen (NPs‑KAg) induced activation 
of innate natural killer (NK) cells, γδ T‑cells and secre‑
tion of innate cytokine IFNα [86]. NPs‑KAg vaccine also 
induced greater frequency of  CD8+ T cells; increased 
secretion of IFN‑γ; lowered frequency of T‑regulatory 
cells; and reduced secretion of inflammatory cytokines 
compared to control KAg‑vaccinated animals [86, 88]. In 
a subsequent study, when NPs‑KAg was co‑administered 
IN with M. tuberculosis WCL adjuvant, a balanced Th1/
Th2 immune response and augmentation of mucosal 
IgA antibody response was observed. After heterologous 
PRRSV challenge, pigs that received NPs‑based vaccine 
showed no clinical signs and also had significant reduc‑
tion in lung virus load [87, 89].
PLGA NPs were also used to encapsulate highly con‑
served influenza peptides and evaluated for efficacy in 
pigs after IN administration. PLGA NPs‑based subunit 
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vaccine resulted in induction of epitope‑specific T‑cell 
response but not the antibody response [61]. The T‑cell 
biased immune response was also observed in pigs after 
IN immunization with PLGA NPs‑encapsulated inac‑
tivated/killed influenza virus (PLGA‑KAg) vaccine in 
pigs [62]. In PLGA‑KAg vaccine administered animals 
observed reduced fever; lowered pneumonic lesions; and 
increased virus clearance from lungs after heterologous 
virus challenge compared to KAg vaccine controls [62].
In another study, PEDV KAg was encapsulated in 
PLGA NPs and used to immunize pregnant sows by IN 
route. This nanovaccine induced higher virus‑specific 
IgG and neutralizing antibodies in serum and greater 
IgG, IgA and neutralizing antibody responses in colos‑
trum. It also induced greater cell proliferation and IFN‑γ 
responses in restimulated PBMCs compared to KAg vac‑
cine controls. Importantly, piglets born to NPs‑vacci‑
nated sows had higher virus neutralizing antibodies and 
were better protected against homologous virus chal‑
lenge than KAg controls [90]. These studies suggest that 
PLGA NPs can be used as an efficient means of enhanc‑
ing virus‑specific cell‑mediated immune responses in 
pigs.
4.3  Polyanhydride‑based NPs
Polyanhydrides are another type of synthetic polymer 
widely studied for vaccine deliveries [91]. Polyanhydride 
NPs are synthesized by polycondensation or emulsifica‑
tion processes and are biodegradable, biocompatible and 
safe for vaccine delivery [91, 92]. They activate innate 
immune responses in a manner similar to lipopolysac‑
charides (LPS) [93]. The surface‑eroding nature of poly‑
anhydride NPs provides safe microenvironment for the 
encapsulated antigens and facilitates slow and sustained 
antigen release [92, 94]. Induction of better antibody and 
cell‑mediated immune responses by polyanhydride NPs‑
based vaccines has been reported against viral, bacterial 
and parasitic infections [48, 91]. Inoculation of polyan‑
hydride NPs‑based SIV KAg vaccine (KAg‑nanovaccine) 
by IN route enhanced cell‑mediated but not the antibody 
responses in pigs [64]. After heterologous virus challenge, 
KAg‑nanovaccine group had six to eightfold reduction of 
nasal virus shedding compared to KAg vaccine controls 
[64]. In a subsequent study, when KAg‑nanovaccine for‑
mulation was supplemented with CpG‑ODN adjuvant, 
both cell‑mediated as well as mucosal IgA antibody 
responses were improved [95]. After heterologous virus 
challenge, CpG‑ODN‑adjuvanted KAg‑nanovaccine pro‑
vided better protection through a significant reduction in 
influenza‑induced fever, 16‑fold reduction of nasal virus 
shedding and 80‑fold reduction in lung virus titers com‑
pared to pigs immunized with five‑times greater quantity 
of soluble killed antigen (KAg) vaccine [95]. This study 
also indicates the dose‑sparing ability of polyanhydride 
NPs. Thus, polyanhydride NPs can also be used to induce 
better cellular as well as humoral immune responses in 
pigs.
4.4  Polysaccharide‑based NPs
Chitosan, alginate and other polysaccharides have also 
attracted attention as materials for NPs formulation 
and drug delivery studies. Chitosan is a natural polymer 
derived from deacetylation of chitin and is composed 
of glucosamine and N‑acetylglucosamine residues [96]. 
Due to the availability of amino and carboxyl groups in 
an acidic microenvironment, chitosan NPs have net posi‑
tive surface charge which makes them highly mucoad‑
hesive and increases their half‑time of antigen retention 
on mucosal surfaces [97, 98]. Further, chitosan NPs can 
reversibly open the epithelial cell tight junctions thereby 
improving paracellular and intracellular antigen trans‑
port across mucosal epithelial surfaces [99, 100]. Chi‑
tosan NPs also enhance antigen uptake by APCs, induce 
APC maturation and active secretion of innate cytokines 
[101, 102]. Thus, chitosan NPs form an attractive mucosal 
vaccine delivery vehicle.
Chitosan‑based NPs are used in pigs to deliver adju‑
vants such as bee venom and plasmid encoding porcine 
IL‑2 and IL‑4/IL‑6 genes, which improved induction of 
better virus‑specific immune responses of respective vac‑
cines against PRRSV and PCV2 [103, 104]. Chitosan NPs 
enhance antigen uptake by porcine APCs and activate 
them to produce innate cytokines including IFN‑alpha, 
TNF‑alpha and IL‑1β [105]. Chitosan NPs encapsu‑
lated SIV KAg (CNPs‑KAg) vaccine administered twice 
through IN route without any additional adjuvant in pigs 
induced the cross‑reactive mucosal IgA antibodies. Chi‑
tosan NPs‑based vaccine also induced IFN‑γ response in 
PBMCs and tracheobronchial lymph nodes (TBLN) bet‑
ter than KAg vaccine controls. This vaccine formulation 
substantially reduced the challenge heterologous virus 
titers by up to 100‑fold in both the upper and lower res‑
piratory tracts compared to soluble KAg vaccine. This 
finding emphasizes the potential benefits of using Chi‑
tosan NPs in future development of mucosal swine influ‑
enza vaccine for pigs [105].
Recently, dendrimer‑like‑alpha‑d‑glucan (Nano‑11) 
NPs derived from sweet corn variety sugary‑1 was exam‑
ined as an alternative, safe, cost‑effective and potent 
adjuvant [106, 107]. Nano‑11 are positively charged NPs 
which efficiently adsorb negatively charged antigens 
through electrostatic interactions. Rodent studies have 
shown that Nano‑11 NPs enhance antigen uptake by 
DCs, induce their maturation, activate them to produce 
pro‑inflammatory cytokines and help in induction of 
antigen‑specific antibodies [106, 107]. In a recent study, 
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we observed that Nano‑11 NPs with or without addition 
of SIV killed antigen (KAg) can stimulate porcine APCs 
and produce cytokines such as IFN‑α, TNF‑α and IL‑1β 
[108]. Pigs immunized via IN route with Nano‑11 NPs 
adsorbed SIV KAg at two‑to‑one ratio (Nano‑11 + KAg) 
resulted in cross‑reactive mucosal IgA responses better 
than KAg controls. Moreover, pigs immunized IM with 
Nano‑11 adsorbed ovalbumin (Nano‑11 + OVA) had 
significantly greater IgG1 and IgG2 antibodies in serum 
compared with pigs vaccinated with OVA alone [108]. 
These findings highlight the possibility of using corn‑
derived Nano‑11 NPs as a potential adjuvant in porcine 
viral vaccine development.
4.5  Liposome‑based NPs
Liposomes can encapsulate both hydrophilic and hydro‑
phobic molecules in aqueous and non‑aqueous phases 
of their vesicles [109]. Liposome vesicles protect anti‑
gens from enzymatic degradation, enhance antigen 
internalization by APCs and maintain controlled release 
of antigens [110]. Liposome‑encapsulated antigens can 
enhance both cellular and humoral immune responses 
[110, 111]. In a pig study, liposome NPs were used as an 
IM adjuvant for a PCV2 DNA vaccine [112]. Liposome 
NPs‑adjuvant induced higher neutralizing antibodies 
and IFNγ response in pigs and reduced viremia of a chal‑
lenge virus compared to alum‑adjuvanted vaccine, pro‑
viding the evidence that liposome NPs can be a potent 
adjuvant in pigs [112]. In our recent study, we used lipo‑
some NPs to encapsulate ten highly conserved peptides 
of different influenza viruses of human and pig origin and 
immunized pigs through IN route co‑administered with 
monosodium urate (MSU) crystal adjuvant [113]. The 
liposome‑adjuvant based vaccine enhanced the mucosal 
IgA antibody response and induced peptide and virus‑
specific T‑helper/memory cells and IFNγ responses 
resulting in reduced fever and modest reduction in virus 
titers in the respiratory tract of pigs [113]. These studies 
highlight the fact that liposome‑based NPs can be used 
as an attractive vaccine delivery platform against porcine 
viral infections.
5  Conclusions and future perspectives
Virus infections have significant impact on pig indus‑
try worldwide. Use of available vaccines have definitely 
helped in achieving strong control over some of the por‑
cine viral infections such as Food and Mouth Disease, 
Transmissible Gastroenteritis, Classical Swine Fever and 
Pseudorabies. Vaccination also helped in reducing the 
clinical signs and increasing the production parameters 
in PCV2‑associated disease. However, for many other 
porcine viruses, further improvements in existing vac‑
cine platforms and development of novel vaccine delivery 
systems are necessary to: (1) Induce better mucosal and 
cell‑mediated immunity; (2) Protect against emerg‑
ing and re‑emerging strains; (3) Enhance the breadth 
(heterologous, cross‑genotype and heterosubtypic) of 
immunity; and (4) Differentiate between infected and 
vaccinated animals.
NPs‑based vaccine delivery platforms such as VLPs, 
biodegradable polymers and liposomes have great poten‑
tial as they—(1) Protect vaccine antigens from degra‑
dation; (2) Facilitate antigen uptake and processing by 
APCs; (3) Impart adjuvant potential; (4) Can be used in 
mucosal and other alternate routes of immunizations; 
and (5) Induce effective mucosal and cellular cross‑pro‑
tective (broader) immunity. Research efforts are ongoing 
to develop porcine viral vaccines using NPs‑based tech‑
nologies. However, more collaboration(s) and in‑depth 
studies are warranted to make this innovative vaccine 
antigen delivery technology successful and practical for 
application in food animal industry. To date, almost all of 
the immunomodulatory mechanisms of NPs‑based vac‑
cine delivery platforms have been studied in rodent dis‑
ease models, which may or may not reflect the situation 
in pigs or other domestic animal species [114]. Likewise, 
proper understanding of effect of size, charge and other 
physicochemical properties of NPs after delivery through 
different routes of immunization in pigs is necessary to 
make efficient translation of this robust NPs‑based vac‑
cine technology. Similarly, studies should also focus on 
NPs stability at different storage conditions and immuno‑
genicity over a long period of time as they will directly 
associate with commercial aspect of the vaccine prod‑
uct. Recent advances in NPs‑based adjuvant and vaccine 
delivery platforms in pigs demonstrate great promise 
to yield better candidate vaccines against many porcine 
viral infections with enhanced efficacy in the field. These 
nanovaccine technologies can also be adopted to develop 
effective vaccines against viral infections in other animal 
species, and knowledge gained could be exploited for 
improving the efficacy of existing human viral vaccines.
Acknowledgements
The research reviewed in this article was supported by Agriculture and Food 
Research Initiative Competitive Grant no. 2013-67015-20476 from the USDA-
NIFA and Nanovaccine Institute (2015–2018), Iowa state University to RGJ. 
Salaries and research supports were provided by the state and federal funds 
appropriated to OARDC. We thank Dr. Steven Krakowka for scientific editing of 
the manuscript.
Authors’ contributions
SD wrote the article; GJR edited and revised the article. Both authors read and 
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Food Animal Health Research Program, Ohio Agricultural Research 
and Development Center, 1680 Madison Avenue, Wooster, OH 44691, USA. 
Page 12 of 14Dhakal and Renukaradhya  Vet Res           (2019) 50:90 
2 Department of Veterinary Preventive Medicine, College of Veterinary Medi-
cine, The Ohio State University, Columbus, OH 43210, USA. 
Received: 28 April 2019   Accepted: 20 October 2019
References
 1. Straub OC (1994) The important viral infections of pigs. Swine Health 
Prod 2:15–18
 2. Meng XJ (2012) Emerging and re-emerging swine viruses. Transbound 
Emerg Dis 59(Suppl 1):85–102
 3. Lunney JK, Fang Y, Ladinig A, Chen N, Li Y, Rowland B, Renukaradhya GJ 
(2016) Porcine reproductive and respiratory syndrome virus (PRRSV): 
pathogenesis and interaction with the immune system. Annu Rev 
Anim Biosci 4:129–154
 4. Holtkamp DJ, Kliebenstein JB, Neumann EJ, Zimmerman JJ, Rotto HF, 
Yoder TK, Wang C, Yeske PE, Mowrer CL, Haley CA (2013) Assessment of 
the economic impact porcine reproductive and respiratory syndrome 
virus on United States pork producers. J Swine Health Prod 21:72–84
 5. Sandbulte MR, Spickler AR, Zaabel PK, Roth JA (2015) Optimal use of 
vaccines for control of influenza A virus in swine. Vaccines 3:22–73
 6. Haden C, Painter T, Fangman T, Holtkamp D (2012) Assessing produc-
tion parameters and economic impact of swine influenza, PRRS and 
Mycoplasma hyopneimoniae on finishing pigs in a large production 
system. In: Proceedings of AASV annual meeting, pp 75–76
 7. Hass J, Matuszewski S, Cieslik D, Haase M (2011) The role of swine as 
“mixing vessel” for interspecies transmission of the influenza A subtype 
H1N1: a simultaneous Bayesian inference of phylogeny and ancestral 
hosts. Infect Genet Evol 11:437–441
 8. Gerdts V, Zakhartchouk A (2017) Vaccines for porcine epidemic diarrhea 
virus and other swine coronaviruses. Vet Microbiol 206:45–51
 9. Langel SN, Paim FC, Lager KM, Vlasova AN, Saif LJ (2016) Lactogenic 
immunity and vaccines for porcine epidemic diarrhea virus (PEDV): 
historical and current concepts. Virus Res 226:93–107
 10. Vlasova AN, Amimo JO, Saif LJ (2017) Porcine rotaviruses: epidemiology, 
immune responses and control strategies. Viruses 9:E48
 11. Stenfeldt C, Diaz-San Segundo F, de Los Santos T, Rodriguez LL, Arzt J 
(2016) The pathogenesis of foot-and-mouth disease in pigs. Front Vet 
Sci 3:41
 12. Brown VR, Bevins SN (2018) A review of classical swine fever virus and 
routes of introduction into the United States and the potential for virus 
establishment. Front Vet Sci 5:31
 13. Schulz K, Staubach C, Blome S (2017) African and classical swine fever: 
similarities, differences and epidemiological consequences. Vet Res 
48:84
 14. Elber AR, Stegeman A, Moser H, Ekker HM, Smak JA, Pluimers FH (1999) 
The classical swine fever epidemic 1997–1998 in The Netherlands: 
descriptive epidemiology. Prev Vet Med 42:157–184
 15. Rose N, Opriessnig T, Grasland B, Jestin A (2012) Epidemiology and 
transmission of porcine circovirus type 2 (PCV2). Virus Res 164:78–89
 16. Karuppannan AK, Opriessnig T (2017) Porcine circovirus type 2 (PCV2) 
vaccines in the context of current molecular epidemiology. Viruses 
9:E99
 17. Streck AF, Canal CW, Truyen U (2015) Molecular epidemiology and 
evolution of porcine parvoviruses. Infect Genet Evol 36:300–306
 18. Muller T, Hahn EC, Tottewitz F, Kramer M, Klupp BG, Mettenleiter TC, 
Freuling C (2011) Pseudorabies virus in wild swine: a global perspective. 
Arch Virol 156:1691–1705
 19. Freuling CM, Muller TF, Mettenleiter TC (2017) Vaccines against pseu-
dorabies virus (PrV). Vet Microbiol 206:3–9
 20. Brown VR, Bevins SN (2018) A review of African swine fever and the 
potential for introduction into the United States and the possibility of 
subsequent establishment in feral swine and native ticks. Front Vet Sci 
5:11
 21. Jeoung HY, Lee WH, Jeong W, Shin BH, Choi HW, Lee HS, An DJ (2011) 
Immunogenicity and safety of virus-like particle of the porcine 
encephalomyocarditis virus in pig. Virol J 8:170
 22. Fan YC, Chen JM, Lin JW, Chen YY, Wu GH, Su KH, Chiou MT, Wu SR, 
Yin JH, Liao JW, Chang GJ, Chiou SS (2018) Genotype I of Japanese 
encephalitis virus virus-like particles elicit sterilizing immunity 
against genotype I and III viral challenge in swine. Sci Rep 8:7481
 23. Nan Y, Wu C, Gu G, Sun W, Zhang YJ, Zhou EM (2017) Improved vac-
cine against PRRSV: current progress and future perspective. Front 
Microbiol 8:1635
 24. Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, Stockhofe-Zur-
wieden N (2009) Challenges for porcine reproductive and respiratory 
syndrome virus (PRRSV) vaccinology. Vaccine 27:3704–3718
 25. Renukaradhya GJ, Meng XJ, Calvert JG, Roof M, Lager KM (2015) Live 
porcine reproductive and respiratory syndrome virus vaccines: cur-
rent status and future direction. Vaccine 33:4069–4080
 26. Renukaradhya GJ, Meng XJ, Calvert JG, Roof M, Lager KM (2015) 
Inactivated and subunit vaccines against porcine reproductive and 
respiratory syndrome: current status and future direction. Vaccine 
33:3065–3072
 27. Renukaradhya GJ, Dwivedi V, Manickam C, Binjawadagi B, Benfield 
D (2012) Mucosal vaccines to prevent porcine reproductive and res-
piratory syndrome: a new perspective. Anim Health Res Rev 13:21–37
 28. Vincent AL, Perez DR, Rajao D, Anderson TK, Abente EJ, Walia RR, 
Lewis NS (2017) Influenza A virus vaccines for swine. Vet Microbiol 
206:35–44
 29. Diaz-San Segundo F, Medina GN, Stenfeldt C, Arzt J, de Los Santos T 
(2017) Foot-and-mouth disease vaccines. Vet Microbiol 206:102–112
 30. Blome S, Moss C, Reimann I, Konig P, Beer M (2017) Classical swine 
fever vaccines-state-of-the-art. Vet Microbiol 206:10–20
 31. Afghah Z, Webb B, Meng XJ, Ramamoorthy S (2017) Ten years of 
PCV2 vaccines and vaccination: is eradication a possibility? Vet Micro-
biol 206:21–28
 32. Xiao CT, Harmon KM, Halbur PG, Opriessnig T (2016) PCV2d-2 is the 
predominant type of PCV2 DNA in pig samples collected in the U.S. 
during 2014–2016. Vet Microbiol 197:72–77
 33. Meszaros I, Olasz F, Csagola A, Tijssen P, Zadori Z (2017) Biology of 
porcine parvovirus (Ungulate parvovirus 1). Viruses 9:E393
 34. Sun Y, Luo Y, Wang CH, Yuan J, Li N, Song K, Qiu HJ (2016) Control 
of swine pseudorabies in China: opportunities and limitations. Vet 
Microbiol 183:119–124
 35. Sanchez-Cordon PJ, Montoya M, Reis AL, Dixon LK (2018) African 
swine fever: a re-emerging viral disease threatening the global pig 
industry. Vet J 233:41–48
 36. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lole-
kha S, Peltola H, Ruff TA, Santosham M, Schmitt HJ (2008) Vaccination 
greatly reduces disease, disability, death and inequity worldwide. Bull 
World Health Organ 86:140–146
 37. Roth JA (2011) Veterinary vaccines and their importance to animal 
health and public health. Procedia Vaccinol 5:127–136
 38. Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM, Fahmy 
TM (2012) Role of sustained antigen release from nanoparticle 
vaccines in shaping the T cell memory phenotype. Biomaterials 
33:4957–4964
 39. Akagi T, Baba M, Akashi M (2012) Biodegradable nanoparticles as vac-
cine adjuvants and delivery systems: regulation of immune responses 
by nanoparticle-based vaccine. In: Kunugi S, Yamaoka T (eds) Polymers 
in nanomedicine. Springer, Berlin, pp 31–64
 40. Joshi VB, Geary SM, Salem AK (2013) Biodegradable particles as vaccine 
delivery systems: size matters. AAPS J 15:85–94
 41. Aoshi T (2017) Modes of action for mucosal vaccine adjuvants. Viral 
Immunol 30:463–470
 42. Coffman RL, Sher A, Seder RA (2010) Vaccine adjuvants: putting innate 
immunity to work. Immunity 33:492–503
 43. Kool M, Fierens K, Lambrecht BN (2012) Alum adjuvant: some of the 
tricks of the oldest adjuvant. J Med Microbiol 61:927–934
 44. Hogenesch H (2012) Mechanism of immunopotentiation and safety of 
aluminum adjuvants. Front Immunol 3:406
 45. Spickler AR, Roth JA (2003) Adjuvants in veterinary vaccines: modes of 
action and adverse effects. J Vet Intern Med 17:273–281
 46. Gerdts V (2015) Adjuvants for veterinary vaccines—types and modes of 
action. Berl Munch Tierarztl Wochenschr 128:456–463
 47. Lycke N (2012) Recent progress in mucosal vaccine development: 
potential and limitations. Nat Rev Immunol 12:592–605
Page 13 of 14Dhakal and Renukaradhya  Vet Res           (2019) 50:90 
 48. Renukaradhya GJ, Narasimhan B, Mallapragada SK (2015) Respiratory 
nanoparticle-based vaccines and challenges associated with animal 
models and translation. J Control Release 219:622–631
 49. Wen ZS, Xu YL, Zou XT, Xu ZR (2011) Chitosan nanoparticles act as an 
adjuvant to promote both Th1 and Th2 immune responses induced by 
ovalbumin in mice. Mar Drugs 9:1038–1055
 50. Tamayo I, Irache JM, Mansilla C, Ochoa-Reparaz J, Lasarte JJ, Gamazo 
C (2010) Poly(anhydride) nanoparticles act as active Th1 adjuvants 
through Toll-like receptor exploitation. Clin Vaccine Immunol 
17:1356–1362
 51. Tandrup Schmidt S, Foged C, Smith Korsholm K, Rades T, Christensen 
D (2016) Liposome-based adjuvants for subunit vaccines: formulation 
strategies for subunit antigens and immunostimulators. Pharmaceutics 
8:E7
 52. Gregory AE, Titball R, Williamson D (2013) Vaccine delivery using nano-
particles. Front Cell Infect Microbiol 3:13
 53. Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK (2007) 
Potent antigen-specific immune responses stimulated by codelivery 
of CpG ODN and antigens in degradable microparticles. J Immunother 
30:469–478
 54. Diwan M, Tafaghodi M, Samuel J (2002) Enhancement of immune 
responses by co-delivery of a CpG oligodeoxynucleotide and tetanus 
toxoid in biodegradable nanospheres. J Control Release 85:247–262
 55. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, 
Samuel J, Lavasanifar A (2008) Co-delivery of cancer-associated antigen 
and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent 
CD8+ T cell-mediated anti-tumor immunity. Vaccine 26:5046–5057
 56. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP (2007) M-cell targeted 
biodegradable PLGA nanoparticles for oral immunization against hepa-
titis B. J Drug Target 15:701–713
 57. Raghuwanshi D, Mishra V, Das D, Kaur K, Suresh MR (2012) Dendritic cell 
targeted chitosan nanoparticles for nasal DNA immunization against 
SARS CoV nucleocapsid protein. Mol Pharm 9:946–956
 58. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V (2002) Rapid 
endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: 
implications for drug and gene delivery. FASEB J 16:1217–1226
 59. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson 
RL, Saltzman WM, Hanlon DJ (2006) Enhanced and prolonged cross-
presentation following endosomal escape of exogenous antigens 
encapsulated in biodegradable nanoparticles. Immunology 117:78–88
 60. Herrmann VL, Hartmayer C, Planz O, Groettrup M (2015) Cytotoxic T cell 
vaccination with PLGA microspheres interferes with influenza A virus 
replication in the lung and suppresses the infectious disease. J Control 
Release 216:121–131
 61. Hiremath J, Kang KI, Xia M, Elaish M, Binjawadagi B, Ouyang K, Dhakal 
S, Arcos J, Torrelles JB, Jiang X, Lee CW, Renukaradhya GJ (2016) Entrap-
ment of H1N1 influenza virus derived conserved peptides in PLGA 
nanoparticles enhances T cell response and vaccine efficacy in pigs. 
PLoS One 11:e0151922
 62. Dhakal S, Hiremath J, Bondra K, Lakshmanappa YS, Shyu DL, Ouyang K, 
Kang KI, Binjawadagi B, Goodman J, Tabynov K, Krakowka S, Narasimhan 
B, Lee CW, Renukaradhya GJ (2017) Biodegradable nanoparticle deliv-
ery of inactivated swine influenza virus vaccine provides heterologous 
cell-mediated immune response in pigs. J Control Release 247:194–205
 63. Lee Y-R, Lee Y-H, Kim K-H, Im S-A, Lee C-K (2013) Induction of potent 
antigen-specific cytotoxic T cell response by PLGA-nanoparticles con-
taining antigen and TLR agonist. Immune Netw 13:30–33
 64. Dhakal S, Goodman J, Bondra K, Lakshmanappa YS, Hiremath J, Shyu 
DL, Ouyang K, Kang KI, Krakowka S, Wannemuehler MJ, Won Lee C, Nar-
asimhan B, Renukaradhya GJ (2017) Polyanhydride nanovaccine against 
swine influenza virus in pigs. Vaccine 35:1124–1131
 65. Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly 
efficient vaccine platform: diversity of targets and production systems 
and advances in clinical development. Vaccine 31:58–83
 66. Ding X, Liu D, Booth G, Gao W, Lu Y (2018) Virus-like particle engi-
neering: from rational design to versatile applications. Biotechnol J 
13:e1700324
 67. Harding CV, Song R (1994) Phagocytic processing of exogenous 
particulate antigens by macrophages for presentation by class I MHC 
molecules. J Immunol 153:4925–4933
 68. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL (1993) Efficient 
major histocompatibility complex class I presentation of exogenous 
antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A 
90:4942–4946
 69. Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF (2017) Major 
findings and recent advances in virus-like particle (VLP)-based vaccines. 
Semin Immunol 34:123–132
 70. Binjawadagi B, Lakshmanappa YS, Longchao Z, Dhakal S, Hiremath J, 
Ouyang K, Shyu DL, Arcos J, Pengcheng S, Gilbertie A, Zuckermann F, 
Torrelles JB, Jackwood D, Fang Y, Renukaradhya GJ (2016) Development 
of a porcine reproductive and respiratory syndrome virus-like-particle-
based vaccine and evaluation of its immunogenicity in pigs. Arch Virol 
161:1579–1589
 71. Van Noort A, Nelsen A, Pillatzki AE, Diel DG, Li F, Nelson E, Wang X 
(2017) Intranasal immunization of pigs with porcine reproductive and 
respiratory syndrome virus-like particles plus 2′, 3′-cGAMP VacciGrade 
adjuvant exacerbates viremia after virus challenge. Virol J 14:76
 72. Pyo HM, Masic A, Woldeab N, Embury-Hyatt C, Lin L, Shin YK, Song JY, 
Babiuk S, Zhou Y (2012) Pandemic H1N1 influenza virus-like particles 
are immunogenic and provide protective immunity to pigs. Vaccine 
30:1297–1304
 73. Crisci E, Fraile L, Moreno N, Blanco E, Cabezon R, Costa C, Mussa T, 
Baratelli M, Martinez-Orellana P, Ganges L, Martinez J, Barcena J, Mon-
toya M (2012) Chimeric calicivirus-like particles elicit specific immune 
responses in pigs. Vaccine 30:2427–2439
 74. Guo HC, Sun SQ, Jin Y, Yang SL, Wei YQ, Sun DH, Yin SH, Ma JW, Liu ZX, 
Guo JH, Luo JX, Yin H, Liu XT, Liu DX (2013) Foot-and-mouth disease 
virus-like particles produced by a SUMO fusion protein system in 
Escherichia coli induce potent protective immune responses in guinea 
pigs, swine and cattle. Vet Res 44:48
 75. Dong YM, Zhang GG, Huang XJ, Chen L, Chen HT (2015) Promising MS2 
mediated virus-like particle vaccine against foot-and-mouth disease. 
Antiviral Res 117:39–43
 76. Pan Q, Wang H, Ouyang W, Wang X, Bi Z, Xia X, Wang Y, He K (2016) 
Immunogenicity of adenovirus-derived porcine parvovirus-like parti-
cles displaying B and T cell epitopes of foot-and-mouth disease. Vaccine 
34:578–585
 77. Wu PC, Lin WL, Wu CM, Chi JN, Chien MS, Huang C (2012) Characteriza-
tion of porcine circovirus type 2 (PCV2) capsid particle assembly and its 
application to virus-like particle vaccine development. Appl Microbiol 
Biotechnol 95:1501–1507
 78. Li W, Wang X, Bai J, Ma T, Li Z, Li Y, Jiang P (2013) Construction and 
immunogenicity of recombinant porcine circovirus-like particles 
displaying somatostatin. Vet Microbiol 163:23–32
 79. Zhang H, Qian P, Peng B, Shi L, Chen H, Li X (2015) A novel subunit 
vaccine co-expressing GM-CSF and PCV2b Cap protein enhances pro-
tective immunity against porcine circovirus type 2 in piglets. Vaccine 
33:2449–2456
 80. Antonis AF, Bruschke CJ, Rueda P, Maranga L, Casal JI, Vela C, Hilgers 
LA, Belt PB, Weerdmeester K, Carrondo MJ, Langeveld JP (2006) A 
novel recombinant virus-like particle vaccine for prevention of porcine 
parvovirus-induced reproductive failure. Vaccine 24:5481–5490
 81. Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as 
biodegradable controlled drug delivery carrier. Polymers 3:1377–1397
 82. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V (2012) 
PLGA-based nanoparticles: an overview of biomedical applications. J 
Control Release 161:505–522
 83. Scholes PD, Coombes AGA, Illum L, Daviz SS, Vert M, Davies MC (1993) 
The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres 
for site-specific drug delivery. J Control Release 25:145–153
 84. Clawson C, Huang CT, Futalan D, Seible DM, Saenz R, Larsson M, Ma 
W, Minev B, Zhang F, Ozkan M, Ozkan C, Esener S, Messmer D (2010) 
Delivery of a peptide via poly(d, l-lactic-co-glycolic) acid nanoparti-
cles enhances its dendritic cell-stimulatory capacity. Nanomedicine 
6:651–661
 85. Blair DA, Turner DL, Bose TO, Pham QM, Bouchard KR, Williams KJ, 
McAleer JP, Cauley LS, Vella AT, Lefrancois L (2011) Duration of antigen 
availability influences the expansion and memory differentiation of T 
cells. J Immunol 187:2310–2321
 86. Dwivedi V, Manickam C, Binjawadagi B, Joyappa D, Renukaradhya 
GJ (2012) Biodegradable nanoparticle-entrapped vaccine induces 
Page 14 of 14Dhakal and Renukaradhya  Vet Res           (2019) 50:90 
cross-protective immune response against a virulent heterologous 
respiratory viral infection in pigs. PLoS One 7:e51794
 87. Binjawadagi B, Dwivedi V, Manickam C, Ouyang K, Wu Y, Lee LJ, Torrelles 
JB, Renukaradhya GJ (2014) Adjuvanted poly(lactic-co-glycolic) acid 
nanoparticle-entrapped inactivated porcine reproductive and respira-
tory syndrome virus vaccine elicits cross-protective immune response 
in pigs. Int J Nanomedicine 9:679–694
 88. Dwivedi V, Manickam C, Binjawadagi B, Renukaradhya GJ (2013) PLGA 
nanoparticle entrapped killed porcine reproductive and respiratory 
syndrome virus vaccine helps in viral clearance in pigs. Vet Microbiol 
166:47–58
 89. Binjawadagi B, Dwivedi V, Manickam C, Ouyang K, Torrelles JB, Renu-
karadhya GJ (2014) An innovative approach to induce cross-protective 
immunity against porcine reproductive and respiratory syndrome virus 
in the lungs of pigs through adjuvanted nanotechnology-based vac-
cination. Int J Nanomedicine 9:1519–1535
 90. Li B, Du L, Yu Z, Sun B, Xu X, Fan B, Guo R, Yuan W, He K (2017) Poly 
(d, l-lactide-co-glycolide) nanoparticle-entrapped vaccine induces a 
protective immune response against porcine epidemic diarrhea virus 
infection in piglets. Vaccine 35:7010–7017
 91. Basu A, Domb AJ (2018) Recent advances in polyanhydride based 
biomaterials. Adv Mater 30:e1706815
 92. Torres MP, Determan AS, Anderson GL, Mallapragada SK, Narasimhan B 
(2007) Amphiphilic polyanhydrides for protein stabilization and release. 
Biomaterials 28:108–116
 93. Petersen LK, Ramer-Tait AE, Broderick SR, Kong CS, Ulery BD, Rajan K, 
Wannemuehler MJ, Narasimhan B (2011) Activation of innate immune 
responses in a pathogen-mimicking manner by amphiphilic polyanhy-
dride nanoparticle adjuvants. Biomaterials 32:6815–6822
 94. Ross KA, Loyd H, Wu W, Huntimer L, Wannemuehler MJ, Carpenter 
S, Narasimhan B (2014) Structural and antigenic stability of H5N1 
hemagglutinin trimer upon release from polyanhydride nanoparticles. J 
Biomed Mater Res A 102:4161–4168
 95. Dhakal S, Ghimire S, Renu S, Ross KA, Lakshmanappa YS, Hogshead BT, 
Bernardo P, Lee CW, Wannemuehler MJ, Narasimhan B, Renukaradhya 
GJ (2019) Evaluation of CpG-ODN-adjuvanted polyanhydride-based 
intranasal influenza nanovaccine in pigs. Vet Microbiol 237:108401
 96. Hejazi R, Amiji M (2003) Chitosan-based gastrointestinal delivery sys-
tems. J Control Release 89:151–165
 97. Lee DW, Lim C, Israelachvili JN, Hwang DS (2013) Strong adhesion and 
cohesion of chitosan in aqueous solutions. Langmuir 29:14222–14229
 98. Lim C, Lee DW, Israelachvili JN, Jho Y, Hwang DS (2015) Contact time- 
and pH-dependent adhesion and cohesion of low molecular weight 
chitosan coated surfaces. Carbohydr Polym 117:887–894
 99. Artursson P, Lindmark T, Davis SS, Illum L (1994) Effect of chitosan on 
the permeability of monolayers of intestinal epithelial cells (Caco-2). 
Pharm Res 11:1358–1361
 100. Dodane V, Amin Khan M, Merwin JR (1999) Effect of chitosan on epithe-
lial permeability and structure. Int J Pharm 182:21–32
 101. Bp Koppolu, Zaharoff DA (2013) The effect of antigen encapsulation in 
chitosan particles on uptake, activation and presentation by antigen 
presenting cells. Biomaterials 34:2359–2369
 102. Hunsawong T, Sunintaboon P, Warit S, Thaisomboonsuk B, Jarman RG, 
Yoon IK, Ubol S, Fernandez S (2015) Immunogenic properties of a BCG 
adjuvanted chitosan nanoparticle-based dengue vaccine in human 
dendritic cells. PLoS Negl Trop Dis 9:e0003958
 103. Lee J, Kim YM, Kim JH, Cho CW, Jeon JW, Park JK, Lee SH, Jung BG, Lee 
BJ (2018) Nasal delivery of chitosan/alginate nanoparticle encapsulated 
bee (Apis mellifera) venom promotes antibody production and viral 
clearance during porcine reproductive and respiratory syndrome virus 
infection by modulating T cell related responses. Vet Immunol Immu-
nopathol 200:40–51
 104. Chen Y, Song T, Xiao YL, Wan X, Yang L, Li J, Zeng G, Fang P, Wang ZZ, 
Gao R (2018) Enhancement of immune response of piglets to PCV-2 
vaccine by porcine IL-2 and fusion IL-4/6 gene entrapped in chitosan 
nanoparticles. Res Vet Sci 117:224–232
 105. Dhakal S, Renu S, Ghimire S, Shaan Lakshmanappa Y, Hogshead BT, 
Feliciano-Ruiz N, Lu F, HogenEsch H, Krakowka S, Lee CW, Renukaradhya 
GJ (2018) Mucosal immunity and protective efficacy of intranasal inac-
tivated influenza vaccine is improved by chitosan nanoparticle delivery 
in pigs. Front Immunol 9:934
 106. Lu F, Mosley Y-YC, Rodriguez Rosales RJ, Carmichael BE, Elesela S, Yao Y, 
HogenEsch H (2017) Alpha-d-glucan nanoparticulate adjuvant induces 
a transient inflammatory response at the injection site and targets 
antigen to migratory dendritic cells. NPJ Vaccines 2:4
 107. Lu F, Mencia A, Bi L, Taylor A, Yao Y, HogenEsch H (2015) Dendrimer-like 
alpha-d-glucan nanoparticles activate dendritic cells and are effective 
vaccine adjuvants. J Control Release 204:51–59
 108. Dhakal S, Lu F, Ghimire S, Renu S, Lakshmanappa YS, Hogshead BT, 
Ragland D, HogenEsch H, Renukaradhya GJ (2019) Corn-derived alpha-
d-glucan nanoparticles as adjuvant for intramuscular and intranasal 
immunization in pigs. Nanomedicine 16:226–235
 109. Schwendener RA (2014) Liposomes as vaccine delivery systems: a 
review of the recent advances. Ther Adv Vaccines 2:159–182
 110. Bernasconi V, Norling K, Bally M, Hook F, Lycke NY (2016) Mucosal 
vaccine development based on liposome technology. J Immunol Res 
2016:5482087
 111. Harding CV, Collins DS, Slot JW, Geuze HJ, Unanue ER (1991) Liposome-
encapsulated antigens are processed in lysosomes, recycled, and 
presented to T cells. Cell 64:393–401
 112. Park C, Jeong J, Choi K, Park SJ, Kang I, Chae C (2017) Development of 
porcine circovirus 2 (PCV2) open reading frame 2 DNA vaccine with 
different adjuvants and comparison with commercial PCV2 subunit 
vaccine in an experimental challenge. Can J Vet Res 81:171–177
 113. Dhakal S, Cheng X, Salcido J, Renu S, Bondra K, Lakshmanappa YS, 
Misch C, Ghimire S, Feliciano-Ruiz N, Hogshead B, Krakowka S, Carson K, 
McDonough J, Lee CW, Renukaradhya GJ (2018) Liposomal nanopar-
ticle-based conserved peptide influenza vaccine and monosodium 
urate crystal adjuvant elicit protective immune response in pigs. Int J 
Nanomedicine 13:6699–6715
 114. Renu S, Dhakal S, Kim E, Goodman J, Lakshmanappa YS, Wannemuehler 
MJ, Narasimhan B, Boyaka PN, Renukaradhya GJ (2018) Intranasal deliv-
ery of influenza antigen by nanoparticles, but not NKT-cell adjuvant 
differentially induces the expression of B-cell activation factors in mice 
and swine. Cell Immunol 329:27–30
 115. Lee C (2015) Porcine epidemic diarrhea virus: an emerging and re-
emerging epizootic swine virus. Virol J 12:193
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
